Fidaxomicin + Vancomycin
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Clostridium Difficile
Conditions
Clostridium Difficile
Trial Timeline
Nov 6, 2014 โ May 5, 2016
NCT ID
NCT02254967About Fidaxomicin + Vancomycin
Fidaxomicin + Vancomycin is a approved stage product being developed by Astellas Pharma for Clostridium Difficile. The current trial status is completed. This product is registered under clinical trial identifier NCT02254967. Target conditions include Clostridium Difficile.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02254967 | Approved | Completed |
Competing Products
20 competing products in Clostridium Difficile